Affordable Access

Publisher Website

20. ß2-Adrenergic agonist treatment inhibits 4T1 breast tumor metastasis to the lung

Brain Behavior and Immunity
DOI: 10.1016/j.bbi.2014.06.040
  • Biology


Solid tumors are composed of neoplastic cells and non-cancerous stromal cells consisting of immune cells, fibroblasts, and endothelial cells. To determine how ß2-adrenergic receptor (ß2-AR) activation of stromal cells influences cancer progression in the absence of tumor cell ß2-AR activation, we utilized the mammary adenocarcinoma 4T1, a murine model of metastatic breast cancer. 4T1 cells do not express functional ß-AR and are unable to respond to ß-AR agonists or the endogenous ß-AR ligand, norepinephrine. BALB/c female mice were injected IP with 5mg/kg salmeterol, a long-acting ß2-AR-selective agonist, or saline beginning 2days before tumor cell injection and continued daily until 24h before sacrifice. In BALB/c mice, salmeterol treatment significantly reduced metastasis to the lungs in association with decreased tumor myeloid derived suppressor cells (CD11b+Gr-1+) and a non-significant reduction in tumor growth. To test if the inhibitory effects of salmeterol were dependent on T cell function, BALB/c SCID mice were treated with salmeterol. In the absence of mature T cells, salmeterol treatment did not reduce lung metastases or tumor growth. These results provide evidence that ß2-AR activation can inhibit tumor growth and metastasis through host ß2-AR-expressing stromal cells including T cells and myeloid derived suppressor cells. Targeting stromal cell ß2-AR may inhibit metastasis in the context of aggressive breast cancer.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Mouse 4T1 breast tumor model.

on Current protocols in immunolog... May 2001

Treatment of stage II lung cancer (T1N1 and T2N1).

on The Surgical clinics of North... October 1987
More articles like this..